L-glutamine

Overview

L-glutamine is the biologically active L-enantiomer of glutamine, a proteinogenic amino acid and one of the most abundant free Amino Acids in human tissues and circulation. It serves as a key nitrogen donor in intermediary metabolism and supports multiple cellular processes, including amino acid biosynthesis, nucleotide synthesis, redox balance, and energy metabolism. Because of these roles, L-glutamine is often described as a conditionally essential amino acid, particularly during physiological stress, illness, or rapid growth.

In biomedical research, L-glutamine is frequently studied in relation to mitochondrial function, immune and intestinal metabolism, and amino-acid–dependent signaling. Recent work has also linked glutamine availability to disease-relevant metabolic rewiring, including cancer metastasis, muscle and joint metabolism, and neuro-metabolic changes. In these contexts, glutamine intersects with pathways involving mitochondrion function, glutamic acid, tryptophan, and broader amino acid networks, and it may be influenced by interventions such as semaglutide, fluoxetine, butyric acid, or engineered microbial therapies.

Focus of Latest Publications

Recent publications have examined L-glutamine in several distinct biomedical contexts, most prominently as a metabolic target in cancer and as a component of supportive or microbiome-based therapies. In oncology-focused work, glutamine metabolism was highlighted as a vulnerability in myeloma and leukemia at the 17th Annual Frontiers in Cancer Science conference, while other studies directly investigated how glutamine pathways contribute to tumor progression, tissue injury, and treatment response. Across these reports, L-glutamine was linked to metabolic adaptation, inflammatory signaling, and tissue repair rather than being treated as a simple nutrient alone.

In squamous cell carcinoma, oxidative stress was shown to induce senescent macrophages in the tumor microenvironment, and integrated metabolomic and transcriptomic analyses identified the glutamine-glutamate pathway as a central metabolic hub. Glutaminase 2 was upregulated to drive glutaminolysis and was associated with IL-1β expression. Mechanistically, IL-1β secreted by senescent macrophages promoted tumor invasion through downregulation of IL-1R2 and activation of NF-κB signaling in SCC cells. Targeting the glutamine metabolism-regulated IL-1β/IL-1R2 axis suppressed invasion, supporting a role for glutamine metabolism in senescence-associated tumor-promoting inflammation.

L-glutamine was also studied in supportive care during carbon-ion radiotherapy for head and neck cancer, where it was combined with β-hydroxy-β-methylbutyrate and arginine in a prospective exploratory study. The rationale was to support tissue repair and protein metabolism during treatment-associated mucositis and dermatitis, although the abstract primarily describes feasibility of continuous oral supplementation rather than reporting efficacy outcomes. In a separate therapeutic context, an engineered probiotic for hepatic encephalopathy was designed to neutralize toxic ammonia and L-glutamine while replenishing essential Amino Acids, indicating interest in glutamine as a systemic metabolic factor in gut-liver-brain axis dysfunction.

Additional recent work connected glutamine metabolism to semaglutide’s effects in osteoarthritis. Using cross-tissue single-cell RNA sequencing and multi-omics analyses, investigators found that semaglutide targeted muscle mitochondria to regulate glutamine metabolism in mice with high-fat diet and osteoarthritis conditions. semaglutide-stimulated muscle mitochondria reduced glutaminase activity, increased circulating glutamine, and alleviated pain and cartilage damage; glutamine produced by C2C12 cells also reduced chondrocyte inflammation in vitro. Together, these studies portray L-glutamine as a recurring metabolic node in cancer invasion, inflammatory signaling, radiotherapy support, hepatic encephalopathy, and muscle-cartilage communication.

Key Publications

• NEWJul Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference. (Cancer research, 2026, PMID 42388021): "the identification of metabolic vulnerabilities, such as the WNK1-mTORC1 axis in leukemia and MAF-driven glutamine metabolism in myeloma."
• NEWJan Outcomes of Supplementation With β-Hydroxy-β-methylbutyrate, Arginine, and Glutamine During Carbon-ion Radiotherapy for Head and Neck Cancer: A Prospective Exploratory Study. (In vivo (Athens, Greece), 2026, PMID 42379751): "Nutritional supplementation using β-hydroxy-β-methylbutyrate (HMB), arginine (Arg), and glutamine (Gln) may support tissue repair and protein metabolism."
• NEWJul Oxidative Stress Induced Senescent Macrophage-Driven Squamous Cell Carcinoma Invasion via Glutamine Metabolic Reprogramming. (Aging cell, 2026, PMID 42333921): "Glutamine, a key substrate supporting oxidative stress defense, has been implicated in TME remodeling and metastasis, yet its specific role in initiating tumor invasion remains unclear."
• NEWJun Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis. (iScience, 2026, PMID 42305583): "The results of multi-omics analysis indicated that semaglutide targeted muscle mitochondria to regulate glutamine metabolism during OA."
• NEWJun Engineered probiotic for hepatic encephalopathy. (Cell host & microbe, 2026, PMID 42269583): "to simultaneously neutralize toxic ammonia and L-glutamine while replenishing essential amino acids"
• Jun Stress Tested: Aging Rewires Tumors for Metastatic Spread through Activation of the Integrated Stress Response. (Cancer research, 2026, PMID 42013364): "The identification of ATF4-driven ISR signaling as a mediator of metastasis highlights new therapeutic vulnerabilities, such as an acquired dependence on glutamine, particularly for older patients who comprise the majority of lung cancer cases."